London, UK, October 10 2017: CN Bio Innovations Limited announces that it has licensed from Vanderbilt University three patents and applications, and
CN Bio Innovations announces license of worldwide rights to Hepatitis B programme from Bristol-Myers Squibb
London, UK, April 5 2017: CN Bio Innovations Limited announces that it has licensed from Bristol-Myers Squibb Company a Hepatitis B drug discovery
Dr Emma Sceats of organ-on-a-chip firm CN Bio Innovations wins Innovate UK’s infocus Women in Innovation award
Welwyn Garden City, UK- 15th November 2016: Following a nationwide competition, CEO of London bioengineering firm CN Bio Innovations Dr Emma Sceats
CN Bio Innovations announces research collaboration with Alnylam
CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is
CN Bio announces research collaboration with gene silencing specialist Benitec Biopharma
CN Bio Innovations, an expert in developing human biomimetic platforms to test and develop therapeutics for liver diseases and infection, is pleased
CN Bio announces opening of new Biosafety Level 3 facility
CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, announced
Imperial College London to present first public HBV data from CN Bio in vitro liver model
CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, has
CN Bio Innovations marks World Hepatitis Day by signing research agreement with Imperial College London
Collaboration will develop and further validate CN Bio’s in vitro model of Hepatitis B liver infection Oxford, UK, 28 July 2014: CN Bio Innovations
Zyoxel Ltd to become CN Bio Innovations Ltd
Zyoxel, an expert in advanced in vitro 3D liver models for drug discovery and drug testing, has today announced it is changing its name to CN Bio